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Purpose: The purpose of this study was to identify factors that influence graft patency and 
limb salvage rates after thrombolysis of occluded infrainguinal vein grafts. 
Methods: The records of patients who tmderwent percutaneous catheter-directed throm- 
bolysis of occluded infrainguinal vein bypass grafts at our institution between 1985 and 
1995 were reviewed. Life table analysis was used to determine survival and patency 
differences. Univariate and multivariate analyses were used to identify the patient-specific 
factors that affected outcomes. 
Results: Forty-four patients with 44 thrombosed infrainguinal vein grafts tmderwent 
thrombotysis with urokinase. The thrombolysis-related mortality rate was 2%, and 
nonfatal complications occurred in 16%. Thrombolysis was tmable to restore graft 
patency in 25% of grafts (11 of 44). Of the remaining 33 successfully sed grafts, 88% 
required adjunctive surgery or percutaneous transluminal ngioplasty after h ombolysis. 
Overall, the primary graft potency rate was 25% at 1 year and 19% at 2 years after 
thrombolysis. Considering only successfully l sed grafts, the primary patency rate im- 
proved to 34% at 1 year and 25% at 2 years. Multivariate analysis revealed that the graft 
patency rate was substantially better in patients without diabetes and in vein grafts that 
had been in place for longer than 12 months (p < 0.01). The limb salvage rate was 
significantly improved by successful thrombolysis (63% at 2 years vs 31% if lysis failed; 
p < 0.01). The patient survival rate was high--89% 2 years after thrombolysis. 
Conclusions: Even with adjunctive therapy, vein graft thrombolysis i unlikely to yield 
durable patency overall. However, successful thrombolysis improves limb salvage rates 
and may be beneficial in patients without diabetes who have mature vein grafts but who 
do not have options for other autogenous revascularization procedures. (J Vasc Surg 
1997;25:1023-32.) 
Management of thrombosed infrainguinal vein 
grafts presents a therapeutic dilemma to the vascular 
surgeon. Should an attempt be made to salvage these 
failed vein grafts, or should entirely new bypass grafts 
be constructed? Thrombolysis has been advocated as 
therapy for failed infrainguinal vein grafts because of 
poor long-term patency rates reported after balloon 
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catheter thrombectomy? ,2 Proponents of catheter- 
directed thrombolysis point out that successful 
thrombolysis may allow immediate interventions to 
correct causes of graft failure or may facilitate more 
focused surgical measures. 37 In addition, patency 
may be restored not only to the graft but also to 
thrombosed collateral and distal arteries that might 
serve as targets for graft extension or replacement. 
Furthermore, lyric therapy appears to inflict less en- 
dothelial injury to the thrombosed vein graft than 
balloon catheter thrombectomy. 8,9 Despite these 
theoretic advantages, however, late results ofinfrain- 
guinal vein graft thrombolysis have not equaled re- 
cently reported results of graft replacement with new 
autogenous vein. 3,x°-t5 Thus it is unclear whether 
and when vein graft thrombolysis might be appropri- 
ate. 
To address this question, we reviewed our expe- 
rience with thrombolysis of occluded infrainguinal 
vein grafts to determine whether specific patient fac- 
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Fig. 1. Clinical outcomes of the 44 patients whose grafts underwent catheter-directed hrom- 
bolysis. 
tors influence subsequent graft patency and limb 
salvage rates. Such data would aid in the selection of 
patients for thrombolysis compared with other ther- 
apeutic alternatives. 
PATIENTS AND METHODS 
The clinical records and arteriograms of all pa- 
tients who underwent catheter-directed thrombo- 
lyric therapy of occluded infrainguinal vein grafts 
from 1985 to 1995 at Dartmouth-Hitchcock Medi- 
cal Center were reviewed. Patients were identified 
using the hospital data base and the patient/proce- 
dure log books of the Section of Interventional Ra- 
diology. 
Forty-four patients (30 male, 14 female) under- 
went thrombolysis of 44 infralnguinal vein grafts that 
had not previously thrombosed. The mean age of the 
patients was 68 + 2 years (+SEM; range, 42 to 87 
years), 86%had a history of cigarette smoking, 63% 
had significant heart disease (a history of myocardial 
infarction, congestive heart failure, or angina), 57% 
were hypertensive and required medication, 34% had 
diabetes (seven insulin dependent, eight non-insulin 
dependent), 25% had chronic renal insufficiency (cre- 
atinine level, >1.5 mg/dl), and 16% had cerebrovas- 
cular disease (a history of transient ischemic attack or 
stroke). A contratateral infrainguinal vein graft was 
present in 16% of these patients. Fourteen percent of 
patients were anticoagulated with warfarin, whereas 
most were taldng aspirin. Thirty-six grafts (82%) 
were initially placed for limb salvage, whereas ix 
(14%) were placed for short-distance clandication 
and two (4%) for treatment of popfiteal aneurysms. 
One bypass graft was to the above-knee popliteal 
artery, 18 were to the below-lmee popliteal artery 
(41%), and 25 were to infrapopliteal vessels (57%). 
Patients with diabetes had more infrapopliteal grafts 
(12 of 15) than patients who did not (12 of 29). In 
situ saphenous vein conduit was used in 27 patients, 
reversed saphenous vein in seven patients, and alter- 
native (lesser saphenous, arm, or spliced) veins in 10 
patients. Of these grafts, 16% were secondary re- 
placements for previously thrombosed vein grafts. 
At the time of graft thrombosis, 43 of 44 patients 
had limb-threatening ischemia (SVS/ISCVS cate- 
gory 4, 5, or 6), whereas one patient had return of 
severe claudication. 16Graft thrombosis occurred at a 
median time of 8 months after initial graft placement 
(range, 1 week to 5.7 years). Patients returned for 
thrombolytic treatment at a median time of 6 days 
after the onset of symptoms of graft occlusion 
(range, 1 to 76 days). 
All grafts underwent a catheter-directed intra- 
graft continuous infusion of urokinase after grafts 
had been probed with a guidewire to demonstrate 
soft thrombus. The mean dose ofurokinase delivered 
was 102,000 units/hour over a mean interval of 30 
hours (median, 27 hours; range, 3 to 97 hours). In 
addition, intravenous heparin was administered toall 
of the patients. These techniques were uniform over 
the period of the study. Failure of thrombolysis was 
defined as the inability to restore blood flow through 
the graft. Resistance scores, graft patency, limb sal- 
vage, and patient survival data after thrombolysis 
were reported according to standards uggested by 
the Ad Hoc Committee on Reporting Standards of 
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Fig. 2. Life table patency rates for grafts for failed infrainguinal vein grafts after attempted 
thrombolysis. 
the Society of Vascular Surgery/North American 
Chapter, International Society for Cardiovascular 
Surgery.16 Fisher's exact est of nominal variables and 
Student's two-tailed t test with Bonferoni's correc- 
tion of continuous variables were used to compare 
factors between groups. Univariate analysis by Cox 
proportional hazards was used to identify factors that 
influenced graft patency and limb salvage rates. Rel- 
ative risks and 95% confidence intervals were calcu- 
lated, with significance determined by the likelihood 
ratio. A multivariate forward stepwise regression 
model (Cox proportional hazards) was used to test 
the validity of the factors identified by univariate 
analysis, with significance determined by the likeli- 
hood ratio. Statistical analysis was performed using 
Statview 4.51 software (Abacus Concepts, Inc., 
Berkeley, Calif.). 
RESULTS 
Of the 44 thrombosed infrainguinal vein grafts, 
33 (75%) were successfully sed, whereas failure to 
restore graft patency occurred in 11 (25%; Fig. 1). 
Successful lysis was more frequent in patients with- 
out diabetes (86% vs 53% in patients with diabetes; 
p = 0.03) and in popliteaMevel grafts (95% vs 58% in 
infrapopliteal grafts; p = 0.01). Of the 33 success- 
fully lysed grafts, 29 (88%) required adjunctive pro- 
cedures to correct a graft stenosis (n = 17), anasto- 
motic stenosis (n = 17), or inflow/outflow disease 
progression (n = 24). To correct hese defects, nine 
grafts underwent balloon angioplasty, 14 underwent 
surgical revision, and six underwent both balloon 
angioplasty and subsequent surgery. Of the balloon 
angioplasty procedures, six were within the vein 
graft, seven were at an anastomoses, seven were in 
the proximal arteries, and five were in the outflow 
arteries (27 dilatations in 15 patients). Of the surgi- 
cal procedures, 14 were vein patch angioplasty pro- 
cedures, five were vein segment replacements, and 
two were vein graft distal extensions. 
After vein graft thrombolysis, the primary pa- 
tency rate ofthrombolysis plus adjunctive procedures 
in all patients was 25% at 1 year and 19% at 2 years 
(Fig. 2). The primary-assisted patency rate was 28% 
at 1 year and 24% at 2 years, whereas the secondary 
patency rate was 33% at 1 year and 26% at 2 years. 
Among the subgroup of patients in whom thrombol- 
ysis was successful, the 1-year and 2-year posttreat- 
ment primary patency rates increased to 34% and 
25%, respectively. 
Of variables available at initial presentation, uni- 
variate analysis of all patients demonstrated that dia- 
betes, infrapopliteal bypass grafting, and graft age 
before thrombosis of less than 12 months were asso- 
ciated with worse patency rates (p < 0.05; Table I). 
Although diabetes was associated with worse pa- 
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Table I. Factors that affect patency 
after thrombolysis 
95% 
Confidence 
Characteristic Relative risk interval p 
Pretreatment factors 
Diabetes 2.6 1.2 to 5.3 0.01 
Graft age < 12 mo before 2.4 1.1 to 5.1 0.02 
thrombosis 
Infrapopliteal bypass 2.4 1.1 to 5.2 0.02 
Female gender 1.8 0.8 to 3.7 0.13 
Chronic renal failure 0.8 0.3 to 1.8 0.52 
(creatinine level, 
1.5 rag/d1) 
No cause for failure 1.2 0.4 to 3.5 0.72 
identified 
Limb salvage 1.1 0.5 to 2.6 0.86 
Alternative venous conduit 1.0 0.4 to 2.3 0.96 
Posttreatment factors 
ABI at discharge (per 0.1 1.3 1.1 to 1.5 0.003 
reduction) 
Resistance score (per 1.0 1.1 1.0 to 1.3 0.09 
increase) 
tency, there was no increased evidence of outflow 
disease in patients with diabetes. Considering vari- 
ables available after treatment, he anlde-brachial in- 
dex (ABI) was the best predictor of longer patency 
(p = 0.02; Table I). A low resistance score after 
treatment (implying little disease in the distal circula- 
tion) approached significance for improved patency 
(p = 0.09). The type of adjunctive procedure (bal- 
loon angioplasty or surgery) did not appear to affect 
patency rates after thrombolysis. 
By multivariate analysis, only diabetes and graft 
age less than 12 months were significant predictors of 
poor posttreatment patency (p < 0.01). On the basis 
of these findings, a Cox proportional hazards model 
was used to evaluate the predicted effect of diabetes 
and graft age on posttreatment patency rates in hy- 
pothetical patients after vein graft thrombolysis. In 
this model, the predicted I-year primary graft pa- 
tency rate for patients without diabetes with graft age 
greater than 12 months was 54%, as compared with a 
2% primary patency rate at 1 year if graft age was less 
than 12 months, a 8% primary patency rate at 12 
months among patients with diabetes, and a 2% pri- 
mary patency rate at 1 year for patients with diabetes 
with graft age less than 12 months (p < 0.01; Fig. 3). 
If posttreatment hemodynamic factors were also 
considered, multivariate analysis revealed that a 
lower posttreatment ABI predicted worse graft pa- 
tency in addition to diabetes and graft age less than 
12 months (p < 0.01). The predicted effects on graft 
patency of diabetes, graft age, and ABI after success- 
ful thrombolysis, based on our modeling, are shown 
in Table II. 
After attempted thrombolysis, the limb salvage 
rate was 56% at 1 and 2 years (Fig. 4). With the 
inclusion of patients who required a second later 
treatment with thrombolysis and further adjunctive 
procedures, the "secondary" limb salvage rate in- 
creased to 63%. However, in the 11 patients in whom 
thrombolysis failed, the limb salvage rate was only 
31% (p < 0.01). Of these 11 patients, one died 
and seven underwent amputation within 3 months 
(Fig. I). Five of these seven amputations were re- 
quired because no distal target artery was identified 
for additional revascularization attempts; one be- 
cause of a lack of autogenous conduit after multiple 
prior bypass procedures; and one because of over- 
whelming infection and tissue loss. In the remaining 
three patients, limb salvage was achieved espite a 
failure to  restore graft patency. This appeared to 
be a result of lysis of thrombus in the distal native 
circulation in two patients who required no further 
therapy and one patient who was able to undergo 
repeat vein bypass grafting 3 months after initial graft 
failure. 
Factors that were identified by univariate analysis 
to be associated with worse limb salvage were diabe- 
tes and infrapopliteal bypass (p < 0.05; Table III). 
Graft age less than 12 months approached signifi- 
cance (p = 0.06). Multivariate analysis of these pa- 
tient characteristics revealed that both diabetes and 
graft age less than 12 months ignificantly predicted 
worse limb salvage rates (p < 0.001). In the subset of 
patients in whom graft thrombolysis was successful, 
identification of disease in the native arterial outflow 
circulation was also predictive of a worse limb salvage 
rate by multivariate analysis (p = 0.003). 
The 30-day mortality rate associated with throm- 
bolysis was 2%, as a result of one patient who died of 
intracranial hemorrhage 6 hours after initiation of 
treatment. Eight nonfatal complications, uch as lo- 
cal hematomas, requirement for transfusion, pneu- 
monia, and cardiac ischemia, occurred in seven pa- 
tients (16%). The late survival rate of all patients was 
94% at 1 year, 89% at 2 years, and 74% at 3 years (Fig. 
5). 
DISCUSSION 
Since 1988 there have been 15 reports of the use 
of thrombolysis and adjuvant therapy in an attempt 
to restore the patency of infrainguinal vein grafts. 
The outcome of this treatment has been difficult to 
determine because only six studies have reported life 
table patency data and most have included both 
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Fig. 3. Predicted patency results after thrombolysis of hypothetical cohorts of patients using a 
Cox proportional hazards model. 
prosthetic mad vein grafts. 3,11qs The largest series 
of vein grafts reported included only 22 patients. 14 
However, the overall results reported in these series 
have been poor, with 1-year primary-assisted patency 
rates after thrombolysis of all infrainguinal vein grafts 
ranging from 23% to 52%. 12J3 Reported results of 
vein graft thrombolysis are also confusing because 
many authors report patency results only in grafts 
that were successfully sed, ignoring those in which 
flow could not ever be restored. In series that re- 
ported only successfully l sed grafts, primary-assisted 
patency rates at 1 year ranged from 17% to 70%, 
compared with 37% in our experience. 3,n,14,1s In our 
series, the grafts of 25% of patients could not be 
successfully lysed, which compares with an initial 
failure rate of 40% reported in another large series by 
Belkin et al.14 After successful thrombolysis, nearly 
all patients required adjunctive surgery or balloon 
angioplasty, 88% in our series and 90% in the report 
of Belkin et al34 In our experience, infrapopliteal 
bypass grafts were much less likely to be successfully 
lysed, and in fact represented 91% of initial lysis 
failures. Thus although we have reported a larger 
series, our I-year graft patency rate of 28% after 
infrainguinal vein graft thrombolysis i  consistent 
with previous reports. 
Fortunately, the limb salvage rate reported after 
vein graft thrombolysis i substantially higher than 
Table II. Effect of ABI on patency 
Graft age < 12 mo 1-yr primary 
Diabetes before thrombosis AB I  patency rate 
Yes Yes 0.5 0% 
Yes No 0.5 7% 
Yes Yes 1.0 11% 
Yes No 1.0 39% 
No No 0.5 35% 
No No 1.0 68% 
No Yes 0.5 5% 
No Yes 1.0 33% 
the graft patency rate, both in our experience and in 
other reports. The limb salvage rate of 67% reported 
by Belkin et al. 14 is comparable with our limb salvage 
rate of 63%. One explanation for this observation 
might be that these limbs were not actually threat- 
ened at the time of graft thrombosis. However, our 
finding that 70% of patients whose vein grafts could 
not be thrombolysed required early amputation sug- 
gests that this is not the case. Lysis of thrombus in 
collateral arteries or distal target arteries for a new 
bypass graft may contribute to this beneficial limb 
salvage ffect. It is also important to note that in the 
achievement of this limb salvage rate, 11 of 33 suc- 
cessfully lysed grafts required later adjunctive proce- 
dures before impending failure or another thrombol- 
ysis treatment sometime after the initial therapy. 
JOURNAL OF VASCULAR SUP~GERY 
1028 Nackman et al. June 1997 
LIMB 
SALVAGE 
1 
0.9 
0.8- 
0.7- 
0.6- 
0.5- 
0.4- 
0.3- 
0.2- 
0.1- 
0 
0 
T 
SUCCESSFUL LYSIS 
i 1 1 1 1 1 
ALL PATIENTS 
LYSIS FAILURES 
I I I I 
01S 1 115 2.6 3 315 4 
YEARS 
Fig. 4. Life table limb salvage results after attempted thrombolysis of failed infrainguinal vein 
grafts. 
Table III. Factors that affect limb 
salvage rates 
95% 
Relative Confidence 
Characteristic risk interval p 
Pretreatment factors 
Diabetes 4.7 1.6 to 13.7 0.002 
Graft age < 12 mo before 2.8 0.9 to 8.9 0.06 
thrombosis 
Infrapopliteal bypass 4.0 1.1 to 14.1 0.02 
Female gender 1.0 0.3 to 3.0 0.98 
Chronic renal failure 1.2 0.4 to 3.7 0.78 
(creafinine l vel, 
1.5 mg/dl)  
Alternative venous conduit 1.2 0.4 to 3.7 0.79 
Posttreatment factors: 
ABI at discharge (per 0.1 1.2 0.9 to 1.5 0.13 
reduction) 
Resistance score (per 1,0 1.2 1,0 to 1.5 0.05 
increase) 
Despite a reasonably high limb salvage rate, the 
poor patency rate after vein graft thrombolysis raises 
the question of whether this approach is appropriate 
or cost-effective. In our patients, there were few 
other options available because most of them had 
already undergone tibial-level bypass procedures and 
because appropriate distal target arteries were not 
apparent on the arteriogram. Only one patient in 
whom thrombolysis was unsuccessful was ultimately 
able to undergo a repeat distal bypass. For this rea- 
son, we applied statistical modeling techniques to 
our results to determine whether any subset of pa- 
tients might benefit from vein graft thrombolysis. 
These results were somewhat more promising. We 
found that patients without diabetes had better e- 
suits, as did more mature vein grafts. Diabetes had 
the most significant negative influence, and this ap- 
peared to be independent of the level of the distal 
vein graft anastomsis. The presence of diabetes pre- 
dicted both a greater likelihood of initial failure to 
restore patency and subsequent poor patency if 
thrombolysis was successful. To emphasize this 
point, only one of 15 patients with diabetes had a 
patent graft 1-year after treatment. This contributes 
to the 60% likelihood of amputation i patients with 
diabetes during this first year. We suspect hat this 
poor outcome in patients with diabetes was caused 
by the severity and more diffuse distribution of distal 
disease that usually exists in these patients. However, 
in the small number of patients with diabetes whose 
grafts were successfully l sed, we could find no statis- 
tically significant evidence that outflow disease was 
more common. Thus we are unable to define the 
specific mechanism for the negative ffect of diabetes 
on graft failure. 
Previous studies have also suggested that more 
mature grafts achieve longer patency after thrombol- 
ysis. In a report of both polytetrafluoroethylene a d 
autogenous vein infrainguinal grafts, Hye et al} 9 
noted a 1-year secondary patency rate of 22% for 
grafts that had been in place more than 1 year, 
compared with only 7% in grafts less than 1 year old 
(p = 0.04). In another combined series ofpolytetra- 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 6 Nackman et al. 1029 
¢¢ 
_> 
~> 
n" 
03 
1- - - I  z 
- -  m 
0.9- 
0.8- 
0.7- 
0.6- 
0.5- 
0.4- 
0.3- 
0.2- 
0.1- 
0 
0 
i i 
I ' I ' ] 
1 2 3 
YEARS 
Fig. 5. Life table patient survival results of patients who underwent thrombolysis of failed 
infrainguinal vein grafts. 
fluoroethylene and vein grafts, Sullivan et al. 3 also 
reported a trend for improved patency rates after 
thrombolysis n older grafts. Our report has statisti- 
cally confirmed this observation i vein grafts using a 
robust, multivariate approach, considering raft age 
as either a continuous variable or comparing rafts in 
place for more or less than 1 year. This observation 
could be a result of several factors. Early graft throm- 
bosis likely reflects inadequate conduit, poor distal 
outflow, or other biologic factors that predict failure 
of the same graft after thrombolysis. Patient-related 
factors such as hypercoagulable states would also 
predictably manifest themselves by early graft throm- 
bosis. Although 20% of patients in our series were 
treated with warfarin after thrombolysis, we did not 
observe a significant effect of this therapy, although 
the number of patients o treated was small. 
If successful thrombolysis occurred we found that 
posttreatment hemodynamic indexes were important 
predictors of subsequent patency. For example, an 
ABI of 0.5 after graft lysis was associated with a 
threefold greater isk of early rethrombosis, com- 
pared with a posttreatment ABI of 1.0. Although this 
observation does not facilitate the selection of pa- 
tients for treatment, it can influence the frequency of 
follow-up surveillance, as well as a consideration of 
elective prophylactic onstruction of a new bypass 
graft, if autogenous conduit is available. This latter 
option would be applicable if graft lysis is successful 
but results in a low ABI. Our model projects that for 
patients without diabetes who have had grafts greater 
than 12 months at the time of thrombosis, the 1-year 
predicted primary patency rate would be 68% if the 
posttreatment ABI is 1.0 (Table II). However, if the 
posttreatment ABI is 0.5, the 1-year primary patency 
rate is predicted to be only 35%. For patients with 
diabetes who had grafts greater than 12 months of 
age at the time of thrombosis, the hemodynamic 
result was especially important. If the posttreatment 
ABI was 0.5 compared with 1.0, the 1-year predicted 
primary patency rate is 7%, as compared with 39%. 
Regardless of the hemodynamic result, patients who 
had both diabetes and grafts less than 12 months had 
an extremely poor predicted patency rate, with 80% 
thrombosed within 6 months despite a posttreat- 
ment ABI of 1.0. 
After successful thrombolysis, identification of 
occlusive disease in the outflow arteries also pre- 
dicted future graft failure. This result, combined with 
our hemodynamic observations, confirms the impor- 
tance of an optimized run-off for maintaining raft 
patency after thrombolysis. Although not proven by 
our study, we believe that duplex graft surveillance 
after successful lysis is important in these high-risk 
grafts, as others have suggested. 12In our series, we 
performed subsequent corrective procedures in seven 
grafts during late surveillance. 
The alternative to vein graft thrombolysis n pa- 
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tients whose limbs are threatened is clearly to replace 
the vein with new autogenous conduit. This tech- 
nique has been advocated by numerous authors, who 
have reported 2-year cumulative patency rates of 5 0% 
to 80% for these secondary vein bypass grafts. 2,1°,17 
This appears to be the best option when autogenous 
vein is available for these secondary reconstructions. 
However, if autogenous vein is not available, the 
secondary patency rate of prosthetic grafts in this 
setting is only 10%, as reported by Whittemore t al. 2 
Thus the optimal treatment for patients whose limbs 
are threatened after infrainguinal vein graft thrombo- 
sis largely depends on the availability of autogenous 
conduit and the identification of appropriate distal 
target arteries. For patients without alternative vein 
or distal target arteries, we believe that the model 
developed in our analysis may help select patients 
who can benefit from vein graft thrombolysis. I f  
patients without diabetes who have vein grafts older 
than 1 year are selected for this therapy, our data 
predict a 2-year primary patency rate of 49% after 
thrombolysis. Though lower than the 80% 2-year 
patency rate for repeat vein bypass reported by De 
Frang, 17 this predicted patency rate of 49% is com- 
parable with the 2-year patency rate reported by 
Whittemore t al.2 for secondary vein grafts, and is 
associated with substantial limb salvage. In patients 
with diabetes who have relatively new vein grafts that 
thrombose, however, the likelihood of benefit after 
thrombolysis  low, and primary amputation may be 
more cost-effective if no other alterative is available. 
An unexpected finding in our study was the rela- 
tively good survival rate of patients after graft throm- 
bolysis. At 2 years, 89% of patients were alive, which 
compares with a 2-year survival rate of 70% in our 
patients who undergo initial infrainguinal bypass 
procedures. 18Furthermore, our survival rate is nearly 
identical to the 84% 2-year survival rate after infrain- 
guinal graft thrombolysis that was reported by Hye 
et al.19 This high survival rate contrasts with a low 
2-year survival rate of 47% that was reported by 
Edwards et al. l° after secondary vein bypass graft 
reconstruction. The explanation for this observation 
is not clear, but the importance of both the graft 
patency rate and the survival rate is obvious. In our 
series, despite a low graft patency rate after throm- 
bolysis, 21% of patients were alive and had a patent 
graft after 2 years. In patients without diabetes who 
had a graft older than 12 months before thrombosis, 
44% of patients were alive with a patent graft at 2 
years. Although Edwards et al.~0 reported a much 
higher patency rate for secondary vein bypass grafts, 
the low survival rate in their series resulted in only 
33% of patients being alive with patent bypass grafts 
at 2 years. This difference in the survival rates of 
apparently comparable patient groups raises the 
question 0fwhether there is some survival advantage 
conferred by the combination of thrombolytic ther- 
apy plus adjuvant treatment as compared with repeat 
vein graft surgery. This possibility was suggested by 
Ouriel et al. 2° in patients who undergo thrombolytic 
treatment for acute limb ischemia, in which the 
6-rnonth survival rate appeared greater than that of 
patients who were treated with initial surgery. Al- 
though our current results cannot prove any survival 
benefit of thrombolytic therapy, our preliminary ob- 
servation of a relatively high survival rate deserves 
additional investigation. 
CONCLUSION 
The purpose of our study was to identify factors 
that allow improved patient selection for thrombo- 
lyric therapy to optimize results in patients with 
thrombosed infrainguinal vein grafts. For patients 
without diabetes who have older vein grafts, throm- 
bolysis may provide significant improvement in pa- 
tcncy rates, particularly if the ABI is high after treat- 
ment. Moreover, given the improved patient survival 
rate after thrombolysis, the results appear compara- 
ble with those of secondary vein bypass procedures. 
However, results indicate that for patients with dia- 
betes who have vein grafts that occlude soon after- 
placement, hrombolytic therapy is unlikely to result 
in durable patency or limb salvage even if newly 
discovered isease within the extremity is corrected. 
When presented with this combination of patient 
factors, the best alternative would be to search for 
• autogenous conduit and an adequate distal target or 
to consider primary amputation. 
We acknowledge the contributions of Nancy A. Cole 
and Paula C. Reynolds in the preparation of this manu- 
script, and Anne G. Alexander, RN, for the collection of 
data. 
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DISCUSSION 
Dr. Michael Belkin (Boston, Mass.). I would like to 
congratulate you on your careful review. As you pointed 
out, your results are remarkably similar to what we found 
when we reported asimilar but smaller series in 1990. Your 
larger numbers and more sophisticated statistical evalua- 
tion, however, allowed you to point out several discrimi- 
nating factors. I think the most important is the age of the 
vein grafts. Old vein grafts are grafts that have stood the 
test of time, and when yon lyse these grafts open you will 
find a normal-looking vein graft with a poor outflow vessel. 
Conversely, when a graft fails early on, it fails because it is a 
terrible graft; when you lyse those veins open you find a 
strictured, iseased vein that nothing is going to make better, 
and therein lies the problem. The few vein grafts that used to 
fail early on as a result of isolated lesions are now picked up 
with our surveillance r gimens and revised so they don't fail. I 
therefore think that you are defining the natural history of bad 
veins. It is not a problem with the lysis per se. 
I also think that the most important message that this 
paper gives is not to simply perform thrombolysis when 
you are confronted with a failed graft. Secondary bypass 
surgery can be very successful when there is an available 
greater saphenous vein. You can expect patency rates ap- 
proaching 70% at 5 years, and when we have used arm or 
lesser saphenous vein the patency rates are 45% at 5 years, 
which is significantly better than what we see here. 
So the $64,000 question is, when a 56-year-old patient 
who does not have diabetes comes back to you on a Friday 
afternoon at 3 o'clock 8 months after undergoing a bypass 
procedure, and he has rest pain because of his failed bypass 
graft, how are you going to treat him? 
Dr. Gary B. Nackman. The decision of what to do 
with that patient without diabetes who has a graft that has 
failed less than 1 year after thrombolysis a difficult issue. 
Clearly between the two factors that we identified, which 
are available to the clinician in the emergency room--the 
presence or absence of diabetes and the age of the graft--  
diabetes had a much more potent effect in our model. In 
fact, out of the 15 patients with diabetes, only one had a 
patent graft after 1 year. In patients without diabetes who 
have a graft that fails early, that is a more difficult problem. 
If  the patient has available conduit vein and if you have a 
distal target on the arteriogram that you proceed with after 
the patient returns, certainly no one would argue that your 
patency results after secondary vein bypass would be far 
superior. However, most of the patients in our series didn't  
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have distal targets available on that arteriogram, and thus 
thrombolysis was merited. 
Dr. Randolph D. Maloney (Beverly, Mass.). I just 
rise to answer the $64,000 question. I went through my 
list of diagnosis-related groups (DRGs) and what the hos- 
pital is getting back for reimbursements as we were listen- 
ing to the talk. Fortunately, the third-party payers are now 
malting us look at this, and I just want to run down the last 
six charges that I have seen on my Medicare patients for 
urokinase lysis: $41,000, $23,000, $39,000, $63,000, 
$69,000, $58,000. Three patients in whom I had to per- 
form thrombectomy and patch angioplasty were $7000 to 
$9000, redo femoropopliteal bypass procedures at 5- and 
9-day stays were anywhere from $12,000 to $18,000. 
Obviously there is a big difference. I think soon an eco- 
nomic decision will be forced on us, and so I think you that 
when you use the urokinase you need to think about how 
much it is going to cost and whose pocket it is coming out 
of. 
Dr. Nackman. Those are all very good comments. 
Certainly in a patient with diabetes whose graft is less than 
12 months old when the graft fails, based on an additional 
model that I didn't have time to demonstrate, if you add in 
the factor ofpostlysis ABI, even if that patient had an ABI 
of i after thrombolysis, the 1-year primary patency rate is 
only 11%, and clearly it would be very difficult for this 
therapy to be cost-effective. We have done some prelimi- 
nary work trying to determine the patient charges and the 
costs. Obviously costs are harder to derive, but our mean 
charge for the thrombolytic therapy--meaning trips to the 
angiography suite, the price of monitoring in the postanes- 
thesia care unit, and the price of the urokinase itself, which 
is quite expensive--is $14,000. The median number is 
$12,000, with a range of $2600 to $32,000. On cost, 
which is approximately 60% to 70% of that number, it 
works out that the mean cost in this series was $11,000 
adjusted for those three items, having nothing to do with 
the whole length of stay. So clearly it is expensive. 
Dr. Paul M. Burke, Jr. (Chelmsford, Mass.). I have a 
couple of questions about your subgroup of patients who 
were on warfarin. Were they therapeutic when they pre- 
sented? If so, did they behave any differently from the 
standpoint of ease of lysis, technical complications, and so 
forth? Were you more liberal with the use of warfarin after 
successful lyric therapy? 
Dr. Nackman. Given the limitations of a retrospective 
study, I cannot comment on how liberal we were with the 
use of warfarin. Fourteen percent of the patients were 
taking warfarin for reasons other than their graft. After 
thrombolysis, an additional 6% of patients were treated 
with warfarin. Of the patients who returned, all of them 
were not therapeutic. Approximately 50% of their admis- 
sion prothrombin times (PTs) were therapeutic with an 
international normalized ratio greater than 1.5. 
Dr. Frank J. Veith (Bronx, N.Y.). In enjoyed your 
paper very much, Dr. Nackman. Dr. Suggs of our group 
has recently reviewed our urokinase data, and unlike your 
results, our results with vein grafts have been abysmal. The 
reason is that these grafts usually consist of extensively 
diseased veins. Have you had any success with such vein 
grafts? My second question relates to the favorable results, 
in terms of limb salvage and patency rates, with lyric ther- 
apy for thrombosed prosthetic grafts. Have you had any 
experience with these, and how do they compare with the 
veins? 
Dr. Nackman. We limited this study to just infraingui- 
nal vein graft thrombolysis for several reasons. First, a good 
quality saphenous vein is a scarce medical resource, and a 
prosthetic graft is fairly inexpensive. We did not perform 
any analysis of patients who have had prosthetic grafts, so I 
cannot comment on that. Regarding the issue of diffusely 
diseased vein graft, over this 10-year time period, although 
this was not a prospective study, all of these grafts were 
followed-up with surveillance duplex scans. It should be 
noted that none of the grafts that failed had any suggestion 
on the prethrombosis duplex scan that something was 
amiss, and this is demonstrated by findings of ABI; we 
looked at the peak systolic velocities, and in some groups 
we looked at graft flow, so we had no indication. This was 
not a prospectively selected series, so it is quite possible 
that in those cases of patients who had horribly diseased 
grafts that were known to the vascular surgeon that throm- 
bosed, no attempt was made at thrombolysis, o I cannot 
comment on that. 
